We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
Read MoreHide Full Article
Moderna (MRNA - Free Report) announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development of an mRNA-based vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans.
Moderna intends to use the above-mentioned funds to support the late-stage development of mRNA-1018, its investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses. Per management, the funding will also help fund the expansion of clinical studies for up to five additional pandemic influenza subtypes.
The company started a phase I/II study on mRNA-1018 in 2023 in healthy adults. Based on positive preliminary data from this study, it is advancing the vaccine to late-stage development. Management also intends to share data from the phase I/II study at a future medical meeting.
This is the second time under a year that Moderna has secured funding from the U.S. government for its bird flu vaccine. Last July, the company was awarded $176 million by the U.S. government to expedite the development of this vaccine.
Earlier this month, the U.S. Centers for Disease Control and Prevention (“CDC”) confirmed the first human death in the country from the H5N1 virus. Though the agency believes that the risk to the general public remains low due to a lack of evidence of human-to-human transmission, it continues to monitor for H5N1 activity, especially in people exposed to animals. As of Jan. 17, the CDC confirmed 67 human cases of H5N1 virus in the country since the beginning of last year.
MRNA Stock Performance
Post the announcement, shares of Moderna were up nearly 5% in after-market trading on Friday. Some investors pointed out that this latest news could help bolster Moderna's financial performance, which faced a major setback last week after management slashed its 2025 revenue guidance.
Unlike traditional vaccines, which can take months to produce, mRNA-based vaccines can be developed quickly and offer manufacturing scalability, something that was observed in the case of COVID-19 vaccines. BARDA believes this to be a major advantage for mRNA vaccines, especially in case new strains/variants of the virus emerge.
The stock has plunged nearly 66% in the past year compared with the industry’s 14.1% decline.
Image Source: Zacks Investment Research
MRNA’s Competition in the Bird Flu Space
Moderna is not the only company to reach an agreement with BARDA for bird flu vaccines. BARDA also has a deal in place for 150 million doses of CSL Seqirus’ protein-based H5N1 bird flu vaccine. In October, CSL received its sixth avian influenza pandemic preparedness award worth $34 million from BARDA.
Another company that is developing its bird flu vaccine is CureVac (CVAC - Free Report) . Last year, CVAC announced that it has started a phase I/II study on its bird flu vaccine. CureVac is developing this investigational mRNA-based vaccine in collaboration with GSK.
Novavax (NVAX - Free Report) is also developing a bird flu vaccine in preclinical studies. NVAX claimed that this vaccine uses a new approach to immunize against the virus.
Image: Bigstock
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab
Moderna (MRNA - Free Report) announced that the U.S. government, through the Biomedical Advanced Research and Development Authority (“BARDA”), has awarded the company $590 million to accelerate the development of an mRNA-based vaccine program aimed at preventing the spread of the H5N1 virus, also known as bird flu, in humans.
Moderna intends to use the above-mentioned funds to support the late-stage development of mRNA-1018, its investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses. Per management, the funding will also help fund the expansion of clinical studies for up to five additional pandemic influenza subtypes.
The company started a phase I/II study on mRNA-1018 in 2023 in healthy adults. Based on positive preliminary data from this study, it is advancing the vaccine to late-stage development. Management also intends to share data from the phase I/II study at a future medical meeting.
This is the second time under a year that Moderna has secured funding from the U.S. government for its bird flu vaccine. Last July, the company was awarded $176 million by the U.S. government to expedite the development of this vaccine.
Earlier this month, the U.S. Centers for Disease Control and Prevention (“CDC”) confirmed the first human death in the country from the H5N1 virus. Though the agency believes that the risk to the general public remains low due to a lack of evidence of human-to-human transmission, it continues to monitor for H5N1 activity, especially in people exposed to animals. As of Jan. 17, the CDC confirmed 67 human cases of H5N1 virus in the country since the beginning of last year.
MRNA Stock Performance
Post the announcement, shares of Moderna were up nearly 5% in after-market trading on Friday. Some investors pointed out that this latest news could help bolster Moderna's financial performance, which faced a major setback last week after management slashed its 2025 revenue guidance.
Unlike traditional vaccines, which can take months to produce, mRNA-based vaccines can be developed quickly and offer manufacturing scalability, something that was observed in the case of COVID-19 vaccines. BARDA believes this to be a major advantage for mRNA vaccines, especially in case new strains/variants of the virus emerge.
The stock has plunged nearly 66% in the past year compared with the industry’s 14.1% decline.
Image Source: Zacks Investment Research
MRNA’s Competition in the Bird Flu Space
Moderna is not the only company to reach an agreement with BARDA for bird flu vaccines. BARDA also has a deal in place for 150 million doses of CSL Seqirus’ protein-based H5N1 bird flu vaccine. In October, CSL received its sixth avian influenza pandemic preparedness award worth $34 million from BARDA.
Another company that is developing its bird flu vaccine is CureVac (CVAC - Free Report) . Last year, CVAC announced that it has started a phase I/II study on its bird flu vaccine. CureVac is developing this investigational mRNA-based vaccine in collaboration with GSK.
Novavax (NVAX - Free Report) is also developing a bird flu vaccine in preclinical studies. NVAX claimed that this vaccine uses a new approach to immunize against the virus.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
MRNA’s Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.